First described in April 2012, MERS-CoV causes severe respiratory illnesses. As of August, 2023, a total of 2605 laboratory-confirmed cases of MERS-CoV and 937 associated deaths have been reported to the World Health Organization (WHO) by 27 countries. More than 2100 cases (~85%) have occurred in Saudi Arabia. The year 2014 had the highest number of reported cases which have declined each year since then. In the United States there have been only 2 imported cases, both diagnosed in May 2014. The virus can spread from person to person and has caused outbreaks in healthcare settings. Approximately 35% of cases have been fatal. The information below addresses laboratory testing.

Testing through Washington State Department of Health (DOH)
All testing must be discussed with and approved by local public health before submission. DOH will forward to Centers for Disease Control and Prevention (CDC) specimens from patients who meet the criteria for further evaluation. The criteria are:

A. Fever AND either pneumonia or acute respiratory distress syndrome (based on clinical or radiologic evidence) AND one of the following:
   - A history of travel from countries in or near the Arabian Peninsula within 14 days before symptom onset, OR
   - Close contact with a symptomatic traveler who developed fever and acute respiratory illness (not necessarily pneumonia) within 14 days after traveling from countries in or near the Arabian Peninsula, OR
   - A member of a cluster of patients with severe acute respiratory illness (e.g., fever and pneumonia requiring hospitalization) of unknown etiology in which MERS-CoV is being evaluated, in consultation with state and local health departments in the United States.

B. Fever AND symptoms of respiratory illness (not necessarily pneumonia; e.g., cough, shortness of breath) AND
   - A history of being in a healthcare facility (as a patient, worker, or visitor) within 14 days before symptom onset in a country or territory in or near the Arabian Peninsula in which recent healthcare-associated cases of MERS have been identified.

C. Fever OR symptoms of respiratory illness (not necessarily pneumonia; e.g., cough, shortness of breath) AND
   - Close contact with a confirmed MERS case while the case was ill.

Countries considered in the Arabian Peninsula and neighboring include: Bahrain; Iraq; Iran; Israel, the West Bank and Gaza; Jordan; Kuwait; Lebanon; Oman; Qatar; Saudi Arabia; Syria; the United Arab Emirates (UAE); and Yemen.
Close contact is defined as:

a) Being within approximately 6 feet (2 meters), or within the room or care area, of a confirmed MERS case for a prolonged period of time (such as caring for, living with, visiting, or sharing a healthcare waiting area or room with a confirmed MERS case) while not wearing recommended personal protective equipment (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection) or

b) Having direct contact with infectious secretions (e.g., being coughed on) of a confirmed MERS case while not wearing recommended personal protective equipment.

See CDC’s Interim Infection Prevention and Control Recommendations for Hospitalized Patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) for more details about protective equipment.

Data to inform the definition of close contact are limited; considerations when assessing close contact include the duration of exposure (e.g., longer exposure time likely increases exposure risk) and the clinical symptoms of the person with MERS (e.g., coughing likely increases exposure risk). Special consideration should be given to those exposed in healthcare settings. For detailed information regarding healthcare personnel please review CDC’s Interim U.S. Guidance for Monitoring and Movement of Persons with Potential Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Transient interactions, such as walking by a person with MERS, are not thought to constitute an exposure; however, final determination should be made in consultation with public health authorities.

Laboratory Testing
Washington State Public Health Laboratories will forward approved specimens to CDC for MERS testing. See: Laboratory Testing for MERS-CoV | CDC

CDC developed a real-time reverse-transcription PCR assay to detect MERS-CoV in respiratory and serum (and in whole blood from infants only) and is the source to laboratory confirm a case tested an any other laboratory in the United States. CDC recommends collecting multiple specimens, including lower (e.g., bronchoalveolar lavage, sputum and tracheal aspirates) and upper (e.g., nasopharyngeal and oropharyngeal swabs) respiratory samples, serum, and stool specimens. See CDC’s MERS-CoV Interim Guidelines for Clinical Specimens from PUI | CDC

Serologic testing for MERS antibodies is currently available at CDC only upon request and approval and is performed if more timely testing is not available. The test is done for surveillance rather than diagnostic purposes.

Use appropriate infection control precautions when collecting specimens for MERS testing. Note that cough-generating procedures, bronchoscopy, or sputum induction are considered aerosol generating procedures. See CDC’s MERS-CoV: Prevention and Control for Hospitalized Patients | CDC

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.